Cullinan Therapeutics Inc.
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
CLN-619
PHASE1
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 30 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma |
Actual Study Start Date : | 2024-09-03 |
Estimated Primary Completion Date : | 2026-09 |
Estimated Study Completion Date : | 2027-03 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Mayo Clinic
Phoenix, Arizona, United States, 85054
RECRUITING
Mayo Clinic
Jacksonville, Florida, United States, 32224
RECRUITING
Mayo Clinic
Rochester, Minnesota, United States, 55905
RECRUITING
Mt. Sinai
New York City, New York, United States, 10029
RECRUITING
Memorial Sloan Kettering (MSK)
New York City, New York, United States, 10065
NOT YET RECRUITING
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
NOT YET RECRUITING
Levine Cancer Institute
Winston-Salem, North Carolina, United States, 27157
RECRUITING
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390